scholarly journals GDSCTools for Mining Pharmacogenomic Interactions in Cancer

2017 ◽  
Author(s):  
Thomas Cokelaer ◽  
Elisabeth Chen ◽  
Francesco Iorio ◽  
Michael P. Menden ◽  
Howard Lightfoot ◽  
...  

AbstractMotivationLarge pharmacogenomic screenings integrate heterogeneous cancer genomic data sets as well as anti-cancer drug responses on thousand human cancer cell lines. Mining this data to identify new therapies for cancer sub-populations would benefit from common data structures, modular computational biology tools and user-friendly interfaces.ResultsWe have developed GDSCTools: a software aimed at the identification of clinically relevant genomic markers of drug response. The Genomics of Drug Sensitivity in Cancer (GDSC) database (www.cancerRxgene.org) integrates heterogeneous cancer genomic data sets as well as anti-cancer drug responses on a thousand cancer cell lines. Including statistical tools (ANOVA) and predictive methods (Elastic Net), as well as common data structures, GDSCTools allows users to reproduce published results from GDSC, to analyse their own drug responses or genomic datasets, and to implement new analytical [email protected]

2019 ◽  
Vol 46 (2) ◽  
pp. 2059-2066 ◽  
Author(s):  
Asghar Arshi ◽  
Sayed Mostafa Hosseini ◽  
Fataneh Saleh Khaje Hosseini ◽  
Zahra Yousefnejad Amiri ◽  
Fatemeh Sadat Hosseini ◽  
...  

Molecules ◽  
2019 ◽  
Vol 24 (9) ◽  
pp. 1749 ◽  
Author(s):  
Lu Jin ◽  
Meng-Ling Wang ◽  
Yao Lv ◽  
Xue-Yi Zeng ◽  
Chao Chen ◽  
...  

Flavonoids are well-characterized polyphenolic compounds with pharmacological and therapeutic activities. However, most flavonoids have not been developed into clinical drugs, due to poor bioavailability. Herein, we report a strategy to increase the drugability of flavonoids by constructing C(sp2)-O bonds and stereo- as well as regioselective alkenylation of hydroxyl groups of flavonoids with ethyl-2,3-butadienoate allenes. Twenty-three modified flavonoid derivatives were designed, synthesized, and evaluated for their anti-cancer activities. The results showed that compounds 4b, 4c, 4e, 5e, and 6b exhibited better in vitro inhibitory activity against several cancer cell lines than their precursors. Preliminary structure–activity relationship studies indicated that, in most of the cancer cell lines evaluated, the substitution on position 7 was essential for increasing cytotoxicity. The results of this study might facilitate the preparation or late-stage modification of complex flavonoids as anti-cancer drug candidates.


2011 ◽  
Vol 108 (46) ◽  
pp. 18708-18713 ◽  
Author(s):  
J.-P. Gillet ◽  
A. M. Calcagno ◽  
S. Varma ◽  
M. Marino ◽  
L. J. Green ◽  
...  

Author(s):  
Guoyi Yan ◽  
Jiang Luo ◽  
Xuan Han ◽  
Wenjuan Zhang ◽  
Chunlan Pu ◽  
...  

BACKGROUND: : Coumarin structures were widely employed in anti-cancer drug design. Herein we focused on the modifications of C4 and C6 positions on coumarin scaffold to get novel anti-cancer agents. OBJECTIVE: The objective of the current work was the synthesis and biological evaluation of a series of 4, 6-coumarin derivatives to get novel anticancer agents. METHODS: Thirty-seven coumarin derivatives were designed and synthesized, the antiproliferative activity of the compounds were evaluated against human cancer cell lines and non-cancerous cells by MTT assay. The bioactivities and underling mechanisms of active molecules were studied and the ADMET characters were predicted. RESULTS: Among the compounds, 4-phydroxy phenol-6-pinacol borane coumarin (25) exhibited a promising anti-cancer activity to cancer cell lines in dose-dependent manner and the toxicity to normal cells was low. The mechanism of action was observed through inducing G2/M phase arrest and apoptosis which was further confirmed via western blot. In silico ADMET prediction revealed that compound 25 is a drug-like small molecule with a favorable safety profile. CONCLUSION: The findings in this work may give vital information for further development of 6-pinacol borane coumarin derivatives as novel anti-cancer agents.


2020 ◽  
Author(s):  
Reine Hanna ◽  
Reem Daouk ◽  
Farah Ballout ◽  
Sarra El-Soussie ◽  
Jad Abdallah ◽  
...  

2019 ◽  
Author(s):  
Steven M. Corsello ◽  
Rohith T. Nagari ◽  
Ryan D. Spangler ◽  
Jordan Rossen ◽  
Mustafa Kocak ◽  
...  

ABSTRACTAnti-cancer uses of non-oncology drugs have been found on occasion, but such discoveries have been serendipitous and rare. We sought to create a public resource containing the growth inhibitory activity of 4,518 drugs tested across 578 human cancer cell lines. To accomplish this, we used PRISM, which involves drug treatment of molecularly barcoded cell lines in pools. Relative barcode abundance following treatment thus reflects cell line viability. We found that an unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines. Moreover, the killing activity of the majority of these drugs was predictable based on the molecular features of the cell lines. Follow-up of several of these compounds revealed novel mechanisms. For example, compounds that kill by inducing PDE3A-SLFN12 complex formation; vanadium-containing compounds whose killing is dependent on the sulfate transporter SLC26A2; the alcohol dependence drug disulfiram, which kills cells with low expression of metallothioneins; and the anti-inflammatory drug tepoxalin, whose killing is dependent on high expression of the multi-drug resistance gene ABCB1. These results illustrate the potential of the PRISM drug repurposing resource as a starting point for new oncology therapeutic development. The resource is available at https://depmap.org.


2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Sanele Mngadi ◽  
Moganavelli Singh ◽  
Seipati Mokhosi

Abstract The use of magnetic nanoparticles (MNPs) has transformed both diagnostics and therapeutic approaches in cancer treatment. Along with developing novel anti-cancer drugs with high therapeutic potential, researchers are exploring innovative strategies for more targeted delivery in order to alleviate the associated potent side effects. In this study, we describe the synthesis of Mg0.5Co0.5Fe2O4 ferrite nanoparticles, their functionalisation with polyvinyl alcohol (PVA), and encapsulation of the anti-cancer drug 5-fluorouracil (5-FU). Functionalised nanoparticles viz. PVA-Mg0.5Co0.5Fe2O4 -5-FU displayed desirable physiochemical properties with regards to the spherical shape, hydrodynamic sizes of <120 nm and relative colloidal stability of up to <−33 mV. The drug encapsulating efficiency was found to be 68%. In vitro cytotoxicity profiles were determined using the MTT and SRB assays, with >65% cell death recorded in MCF-7 and HeLa cancer cell lines. Overall, the nanocomposites exhibited excellent physiochemical elements, high specificity towards cancerous cells and displayed pH-sensitive drug release in a simulated acidic tumour micro-environment. The encapsulation of 5-FU improved bioavailability of the drug in cancer cell lines for a prolonged duration, with the promise to enhance its therapeutic effect, biocompatibility and safety. These MNPs present as promising in vitro delivery systems that can further developed for therapeutic applications.


2021 ◽  
Vol 18 ◽  
Author(s):  
Tran Khac Vu ◽  
Bach Xuan Nguyen ◽  
Linh Nguyen Pham Duy ◽  
Thuc Bao Nguyen Truong ◽  
Anh Tuan Phung ◽  
...  

Background: In this study, two novel hybrid series of artemisinin and quinazolinones were synthesized and evaluated in vitro cytotoxicity against two human cancer cell lines, including SKLu-1 (lung cancer), MCF- 7 (breast cancer). The bio-assay results indicated that most of the target compounds exhibited cytotoxic activities against both human cancer cell lines tested, and seemed to be more cytotoxic toward the breast (MCF-7) cancer cells than lung (SKLu-1) cancer cells. Among the synthesized artemisinin hybrids, the compound 13d containing a quinazolinone conjugated system exhibited the most potent cytotoxicity against the SKLu-1 and MCF-7 cell lines with IC50 values of 1.62 and 0.77 µM, respectively. Objective: This study aims at developing novel hybrids of artemisinin and quinazolinones as anti-cancer agents. Method: A series of novel hybrids were designed, synthesized and evaluated for cytotoxicity against two human cancer cell lines, including SKLu-1 and MCF-7 using SRB method. Results : All thirteen hybrids of artemisinin with quinazolinone exhibited cytotoxic activity against two tested cancer cell lines, in which the compound 13d exhibited the most potent cytotoxicity against the SKLu-1 and MCF-7 cell lines with IC50 values of 1.62 and 0.77 µM, respectively. Conclusion: The research results suggest that some compounds could be considered as leads for future design of hybrids and have the potential for further studies in the field of anti-cancer agent development.


Sign in / Sign up

Export Citation Format

Share Document